News & Events about Amyris Inc.
Amyris (NASDAQ:AMRS Get Rating) had its price objective lowered by equities research analysts at Piper Sandler from $1.50 to $1.00 in a research note issued on Wednesday, The Fly reports. Piper Sandlers price objective would indicate a potential upside of 28.82% from the stocks...
Simply Wall St
5 months ago
Key Insights Significantly high institutional ownership implies Amyris' stock prices are sensitive to their trading...
AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT AMYRIS ANNOUNCES $50 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT PR Newswire EMERYVILLE, Calif., Dec. 29, 2022 EMERYVILLE, Calif., Dec. 29, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq...
AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION AMYRIS SUCCESSFULLY ADVANCES STRATEGIC TRANSACTION PR Newswire EMERYVILLE, Calif., Dec. 27, 2022 EMERYVILLE, Calif., Dec. 27, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's...